In the primary EarlyR cohort of all ER+ breast cancer patients (N = 1174), EarlyR score (Figure 2A) classified 67% of patients as low risk (EarlyR-Low), 19% as intermediate risk (EarlyR-Int), and 14% as high risk (EarlyR-High). The gene discussed is ESR1; the disease is breast cancer.